Modified Tafazzin Proteins And Methods Of Making And Using The Same

Abstract

Fusion proteins comprising a tafazzin peptide and a cellular permeability peptide are disclosed. The tafazzin peptide may be coupled to the permeability peptide through a polypeptide linker. Methods of making and using the fusion proteins are also disclosed. For example, the disclosed fusion proteins may be used to treat a patient having a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency (e.g., Barth syndrome). Additionally, the disclosed fusion proteins may be used in prophylaxis against developing a disorder associated with a tafazzin deficiency or a remodeled cardiolipin deficiency in a patient at risk of developing such a disorder.


Claims
Owners (US)

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Jan 24, 2017
  • Application: Jan 22, 2015
    US US 201514603141 A
  • Priority: Jan 22, 2015
    US US 201514603141 A
  • Priority: Jan 22, 2014
    US US 201461930264 P

Download Citation


Sign in to the Lens

Feedback